Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.

Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal significantly undervalues the company and does not align with shareholder ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

Having witnessed a 90%-plus stock price slide during recent years, Sage Therapeutics’ leadership must decide whether now is the right time to accept a buyout offer. Biogen has offered to ...

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...